Last updated on February 2019

Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment


Brief description of study

The primary objectives of this study are to evaluate the effect of Obeticholic Acid treatment compared to placebo on 1) histological improvement and 2) liver-related clinical outcomes in patients with non-cirrhotic nonalcoholic steatohepatitis (NASH) with liver fibrosis.

Clinical Study Identifier: NCT02548351

Find a site near you

Start Over

The University of Vermont Medical Center

Burlington, VT United States
2.33miles
  Connect »